A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation
Molecules · 2026
DOI: 10.3390/molecules31040582 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Erica Gazzillo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy. Hauptthemen laut MEDLINE: Transcription Factors, Bromodomain Containing Proteins. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'università e della ricerca, AIRC, AIRC under MFAG 2017.
Abstract (Originalsprache)
Bromodomain-containing protein 9 (BRD9) belongs to the non-canonical BAF chromatin remodeling complex and represents a relevant therapeutic target in pathologies featuring dysregulated epigenetic control. The absence of clinically validated inhibitors and the need for diversified chemical entities highlight the interest in identifying new scaffolds targeting this protein. In this study, Saturation Transfer Difference Nuclear Magnetic Resonance (STD NMR) was employed to assess its suitability for characterizing BRD9–ligand interactions within a fragment-based discovery framework. STD NMR conditions were first optimized using the known BRD9 ligand 1, verifying the presence of interaction signals. A pharmacophore-based virtual screening campaign was then performed using libraries of commercially available fragments, leading to the selection of a novel isatin derivative, i.e., compound 2, whose binding was demonstrated in AlphaScreen assays. STD NMR experiments provided epitope mapping consistent with the predicted binding mode, thus supporting the stability of the interaction in solution. Moreover, a competitive STD experiment demonstrated displacement of 2 by a reference ligand, confirming the binding within the canonical BRD9 pocket. Overall, this study establishes STD NMR as a reliable approach for probing BRD9–ligand interactions and for the identification and validation of BRD9-targeting scaffolds suitable for future structure-guided optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084 Fisciano, Italy.
- Institute for Chemical Research (IIQ), CSIC-University of Seville, 49 Américo Vespucio St, 41092 Seville, Spain.
- Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, 86090 Pesche, Italy.
ORCID-Profile: Gabriel Rocha, Gianluigi Lauro, Jesús Angulo
Förderung
- Ministero dell'università e della ricerca
- AIRC
- AIRC under MFAG 2017
- PRIN 2022
Zitieren
APA
Gazzillo, E., Rocha, G., Chini, M. G., Lauro, G., Angulo, J., & Bifulco, G. (2026). A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation. Molecules. https://doi.org/10.3390/molecules31040582
Vancouver
Gazzillo E, Rocha G, Chini MG, Lauro G, Angulo J, Bifulco G. A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation. Molecules. 2026. doi:10.3390/molecules31040582
BibTeX
@article{Gazzillo2026,
author = {Gazzillo, Erica and Rocha, Gabriel and Chini, Maria Giovanna and Lauro, Gianluigi and Angulo, Jesús and Bifulco, Giuseppe},
title = {A 5-Br-1-Propylisatin Derivative as a Promising BRD9 Ligand: Insights from Computational and STD NMR Investigation},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31040582}
}
EUVIMED